WORK Medical Technology Group LTD Announces 1-for-100 Reverse Stock Split Effective October 21, 2025

Rhea-AI Summary

WORK Medical Technology Group (Nasdaq: WOK) will effect a 1-for-100 reverse stock split effective October 21, 2025, with Class A shares trading on a post-split basis from market open that day under the existing ticker WOK and new CUSIP G9767H117.

The split was approved by shareholders and the board to regain compliance with Nasdaq Rule 5550(a)(2). Fractional shares will be rounded up to the next whole share. Outstanding Class A shares will fall from approximately 96.00 million to 960,000; Class B shares will fall from approximately 7.59 million to 76,000.

Positive

• Outstanding Class A shares cut from ~96.00M to ~960,000
• Outstanding Class B shares cut from ~7.59M to ~76,000
• Action intended to regain compliance with Nasdaq Rule 5550(a)(2)

Negative

• Reverse split may reduce post-split trading liquidity for shareholders
• Rounding up fractional shares may slightly alter ownership percentages for some holders

Insights

Corporate actions analyst

Reverse 1-for-100 split to regain Nasdaq bid-price compliance; share count reduced, ownership percentages largely unchanged.

WORK MedicalOctober 21, 2025, reducing Class A from ~96.00 million to ~960,000 and Class B from ~7.59 million to ~76,000.

The action restores compliance with Nasdaq Marketplace Rule 5550(a)(2) by raising the per‑share nominal price. The split does not change economic ownership except for tiny effects from rounding up fractional shares, which the company will convert to whole shares.

Key risks include continued inability to maintain the minimum bid price after the split and potential short‑term volatility when trading resumes on October 21, 2025. Monitor post‑split bid price, volume, and any further Nasdaq notices over the next 30 to 90 days.

Hangzhou, China, Oct. 16, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced that it will effect a reverse stock split of its ordinary shares on a 1-for-100 basis (the “Reverse Stock Split”). The Company’s Class A ordinary shares will begin trading on a post-split basis when the market opens on October 21, 2025. The Company’s Class A ordinary shares will continue to trade on the Nasdaq Capital Market under the symbol “WOK,” with a new CUSIP number G9767H117.

The Reverse Stock Split has been approved by the Company’s shareholders and the Company’s board of directors, and is being effectuated primarily to regain compliance with Nasdaq Marketplace Rule 5550(a)(2) relating to the maintenance of the minimum bid price per share of the Company’s Class A ordinary shares.

Any fractional shares that would have otherwise resulted from the Reverse Stock Split will be rounded up to the next whole number and no fractional shares will be issued. The Reverse Stock Split affects all shareholders uniformly and will not alter any shareholder’s percentage interest in the Company’s outstanding ordinary shares, except for adjustments that may result from the rounding up of fractional shares.

Upon the effectiveness of the Reverse Stock Split, every one hundred shares of the Company’s issued and outstanding Class A ordinary shares as of the effective date will automatically be combined into one Class A ordinary share, and every one hundred shares of the Company’s issued and outstanding Class B ordinary shares as of the effective date will automatically be combined into one Class B ordinary share. Such adjustments will reduce the total number of outstanding Class A ordinary shares of the Company from approximately 96.00 million to approximately 960,000, and the total number of outstanding Class B ordinary shares of the Company will be reduced from approximately 7.59 million to approximately 76,000.

About WORK Medical Technology Group LTD

WORK Medical Technology Group LTD, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, is a supplier of medical devices that develops and manufactures Class I and II medical devices and sells Class I and II disposable medical devices through operating subsidiaries in China. The Company has a diverse product portfolio comprising 21 products, including customized and multifunctional masks and other medical consumables. All the products have been sold in 34 provincial-level administrative regions in China, with 15 of them sold in more than 30 countries worldwide. The Company has received a number of quality-related manufacturing designations and has registered 17 products with the U.S. Food and Drug Administration allowing their products to enter the U.S. market. For more information, please visit the Company’s website: https://www.workmedtech.com/corporate.

Forward-Looking Statements

This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Any forward-looking statements in this press release are based on the Company’s current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results set forth in the Company’s annual report on Form 20-F and other documents filed by the Company with the U.S. Securities and Exchange Commission. The Company explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

For more information, please contact:

WORK Medical Technology Group LTD
Investor Relations Department
Email: ir@workmedtech.com

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com

FAQ

What is WORK Medical (WOK) doing on October 21, 2025?

WORK Medical will implement a 1-for-100 reverse stock split and Class A shares will trade on a post-split basis when markets open on October 21, 2025.

How many WOK shares will be outstanding after the reverse split?

Outstanding Class A shares will fall to about 960,000 and Class B shares to about 76,000 after the split.

Why did WORK Medical (WOK) approve the 1-for-100 reverse split?

The company said the reverse split is being effected primarily to regain compliance with Nasdaq Rule 5550(a)(2) on minimum bid price.

Will WOK keep the same ticker after the reverse split?

Yes. The Class A ordinary shares will continue to trade on Nasdaq under the symbol WOK, with a new CUSIP G9767H117.

How are fractional WOK shares handled in the reverse split?

Any fractional shares resulting from the reverse split will be rounded up to the next whole share; no fractional shares will be issued.

Will the reverse split change my percentage ownership of WOK?

The reverse split is intended to affect all shareholders uniformly and not alter percentage ownership, except for small adjustments from fractional-share rounding.